BACKGROUND: Prostatitis accounts for 2 million outpatient visits annually. The majority of prostatitis cases fit the definition of chronic pelvic pain syndrome, for which routine antibiotic use is not indicated. METHODS: Inpatient, outpatient, and pharmacy datasets from the Veterans Health Administration were used to quantify the magnitude of antibiotic use attributable to chronic pelvic pain syndrome. Specifically, men with a diagnosis of infectious/acute prostatitis or a urinary tract infection were excluded, and the remaining men with a diagnosis of prostatitis were defined as having chronic pelvic pain syndrome. RESULTS: The annual prevalence of chronic pelvic pain syndrome was 0.5%. Prescriptions for fluoroquinolone antibiotics were filled in 49% of men with a diagnosis of chronic pelvic pain syndrome compared with 5% in men without chronic pelvic pain syndrome. Men with chronic pelvic pain syndrome were more than 7 times more likely to receive a fluoroquinolone prescription independently of age, race/ethnicity, and comorbid conditions. Increased use of other antibiotics also was observed. High use was similar in men with either infectious/acute prostatitis or chronic pelvic pain syndrome. CONCLUSION: Despite evidence that antibiotics are not effective in the majority of men with chronic pelvic pain syndrome, they were prescribed in 69% of men with this diagnosis. Some increased use is probably due to uncontrolled confounding by comorbid conditions or inaccurate diagnostic coding. However, a 7-fold higher rate of fluoroquinolone usage suggests that strategies to reduce unnecessary antibiotic use in men with prostatitis are warranted.
BACKGROUND:Prostatitis accounts for 2 million outpatient visits annually. The majority of prostatitis cases fit the definition of chronic pelvic pain syndrome, for which routine antibiotic use is not indicated. METHODS: Inpatient, outpatient, and pharmacy datasets from the Veterans Health Administration were used to quantify the magnitude of antibiotic use attributable to chronic pelvic pain syndrome. Specifically, men with a diagnosis of infectious/acute prostatitis or a urinary tract infection were excluded, and the remaining men with a diagnosis of prostatitis were defined as having chronic pelvic pain syndrome. RESULTS: The annual prevalence of chronic pelvic pain syndrome was 0.5%. Prescriptions for fluoroquinolone antibiotics were filled in 49% of men with a diagnosis of chronic pelvic pain syndrome compared with 5% in men without chronic pelvic pain syndrome. Men with chronic pelvic pain syndrome were more than 7 times more likely to receive a fluoroquinolone prescription independently of age, race/ethnicity, and comorbid conditions. Increased use of other antibiotics also was observed. High use was similar in men with either infectious/acute prostatitis or chronic pelvic pain syndrome. CONCLUSION: Despite evidence that antibiotics are not effective in the majority of men with chronic pelvic pain syndrome, they were prescribed in 69% of men with this diagnosis. Some increased use is probably due to uncontrolled confounding by comorbid conditions or inaccurate diagnostic coding. However, a 7-fold higher rate of fluoroquinolone usage suggests that strategies to reduce unnecessary antibiotic use in men with prostatitis are warranted.
Authors: M McNaughton Collins; M A Pontari; M P O'Leary; E A Calhoun; J Santanna; J R Landis; J W Kusek; M S Litwin Journal: J Gen Intern Med Date: 2001-10 Impact factor: 5.128
Authors: Richard B Alexander; Kathleen J Propert; Anthony J Schaeffer; J Richard Landis; J Curtis Nickel; Michael P O'Leary; Michel A Pontari; Mary McNaughton-Collins; Daniel A Shoskes; Craig V Comiter; Nand S Datta; Jackson E Fowler; Robert B Nadler; Scott I Zeitlin; Jill S Knauss; Yanlin Wang; John W Kusek; Leroy M Nyberg; Mark S Litwin Journal: Ann Intern Med Date: 2004-10-19 Impact factor: 25.391
Authors: J Curtis Nickel; Joe Downey; Janet Clark; Richard W Casey; Peter J Pommerville; Jack Barkin; Gary Steinhoff; Gerald Brock; Allan B Patrick; Stanley Flax; Bernard Goldfarb; Bruce W Palmer; Joseph Zadra Journal: Urology Date: 2003-10 Impact factor: 2.649
Authors: T E Bjerklund Johansen; R N Grüneberg; J Guibert; A Hofstetter; B Lobel; K G Naber; J Palou Redorta; P J van Cangh Journal: Eur Urol Date: 1998-12 Impact factor: 20.096
Authors: Min-Woong Sohn; Huiyuan Zhang; Noreen Arnold; Kevin Stroupe; Brent C Taylor; Timothy J Wilt; Denise M Hynes Journal: Popul Health Metr Date: 2006-07-06